Actively Recruiting
4D-150 in Patients With Neovascular (Wet) Age-Related Macular Degeneration
Led by 4D Molecular Therapeutics · Updated on 2026-02-12
215
Participants Needed
25
Research Sites
472 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Phase 1/2 dose-escalation and randomized, controlled, masked expansion trial in adults with wet AMD undergoing active anti-VEGF treatment. Substudies will evaluate the safety and tolerability of 4D-150 contralateral eye dosing and characterize vector shedding.
CONDITIONS
Official Title
4D-150 in Patients With Neovascular (Wet) Age-Related Macular Degeneration
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Be 50 years of age or older
- Diagnosed with choroidal neovascularization secondary to age-related macular degeneration confirmed by reading center
- Best corrected visual acuity (BCVA) of 34 ETDRS letters (~20/200) or better in the contralateral eye
- Central subfield thickness and/or presence of subretinal or intraretinal fluid requiring ongoing anti-VEGF therapy in the study eye, confirmed by SD-OCT and reading center
- Study eye suitable for intravitreal injection
- Ability to perform visual and retinal function tests and comply with protocol procedures
- Currently receiving anti-VEGF treatment in the study eye and demonstrated clinical response within 12 months prior to screening
- Agree to use barrier methods during intercourse for 6 months after 4D-150 administration; sexually active males must not father a child or donate sperm during this period
- Medical records documenting anti-VEGF therapy history for at least 12 months prior to screening
- Provide written informed consent
- For Contralateral Eye Sub-study: received 4D-150 in study eye-1 at least 6 months prior to screening
- Macular neovascularization secondary to AMD in study eye-2 confirmed by imaging
- History of at least one anti-VEGF injection in study eye-2 within 6 months prior to screening
- BCVA between 25 and 83 ETDRS letters in study eye-2
- Study eye-2 suitable for intravitreal injection
- BCVA of 34 ETDRS letters or better in previously treated study eye-1
- Ability to comply with protocol procedures and visits
- Agree to use barrier methods as above
- Provide written informed consent
- For Shedding Substudy: 50 years or older
- Diagnosed with macular neovascularization secondary to AMD confirmed by imaging
- BCVA between 10 and 83 ETDRS letters in study eye at screening
- BCVA of 34 ETDRS letters or better in contralateral eye
- Currently receiving anti-VEGF treatment in study eye with at least one injection in last 6 months
- Study eye suitable for intravitreal injection
- Ability to perform visual and retinal function tests and comply with protocol procedures
- Agree to use barrier methods as above
- Provide written informed consent
You will not qualify if you...
- None explicitly stated in the eligibility criteria
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 25 locations
1
Barnet Delaney Perkins Eye Center
Phoenix, Arizona, United States, 85016
Actively Recruiting
2
California Retina Consultants
Oxnard, California, United States, 93036
Actively Recruiting
3
Retinal Consultants Medical Group
Sacramento, California, United States, 95841
Actively Recruiting
4
Colorado Retina Associates
Lakewood, Colorado, United States, 80288
Actively Recruiting
5
Rand Eye Institute
Deerfield Beach, Florida, United States, 33064
Suspended
6
Retina Vitreous Consultants, LLP DBA Retina Group of Florida
Fort Lauderdale, Florida, United States, 33308
Active, Not Recruiting
7
Vitreo Retinal Associates
Gainesville, Florida, United States, 32607
Actively Recruiting
8
Florida Eye Associates
Melbourne, Florida, United States, 32901
Actively Recruiting
9
Retinal Specialty Institute
Pensacola, Florida, United States, 32503
Actively Recruiting
10
Retina Vitreous Associates of Florida
Tampa, Florida, United States, 33607
Actively Recruiting
11
University Retina and Macula Associates
Oak Forest, Illinois, United States, 60452
Actively Recruiting
12
Retina Partners Midwest
Carmel, Indiana, United States, 46290
Actively Recruiting
13
Cumberland Valley Retina Consultants
Hagerstown, Maryland, United States, 21740
Actively Recruiting
14
Ophthalmic Consultants of Boston & Boston Eye Surgery and Laser Center
Boston, Massachusetts, United States, 02114
Actively Recruiting
15
Sierra Eye Associates
Reno, Nevada, United States, 89502
Actively Recruiting
16
Western Carolina Retinal Associates
Asheville, North Carolina, United States, 28803
Withdrawn
17
Verum Research, LLC
Eugene, Oregon, United States, 97401
Actively Recruiting
18
Mid Atlantic Retina
Bethlehem, Pennsylvania, United States, 18017
Actively Recruiting
19
Palmetto Retina Center, LLC
West Columbia, South Carolina, United States, 29169
Actively Recruiting
20
Tennessee Retina
Nashville, Tennessee, United States, 37203
Actively Recruiting
21
Austin Clinical Research
Austin, Texas, United States, 78750
Actively Recruiting
22
Valley Retina Institute, PA
McAllen, Texas, United States, 78503
Actively Recruiting
23
Retina Consultants of Texas
The Woodlands, Texas, United States, 77384
Withdrawn
24
Pacific Northwest Retina LLC
Bellevue, Washington, United States, 98004
Withdrawn
25
Emanuelli Research and Development Center, LLC
Arecibo, Puerto Rico, Puerto Rico, 00612
Actively Recruiting
Research Team
4
4DMT Patient Advocacy
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
10
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here